Consistent with previous studies, LUAD tumors harboring EGFR/TP53/RB1 co‐alterations are more likely to undergo SCLC transdifferentiation into SCLC [22], a phenotypic switch contributing to acquired resistance to EGFR inhibitors [25]. The gene discussed is TP53; the disease is small cell lung carcinoma.